NexgenRx (NXG) Insider Trading & Ownership C$0.28 -0.01 (-1.79%) (As of 10/22/2024) Add Compare Share Share Insider Trades Stock AnalysisChartEarningsInsider Trades NexgenRx (CVE:NXG) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage36.79%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)C$38,600.00Number OfInsiders Selling(Last 12 Months)0 Get NXG Insider Trade Alerts Want to know when executives and insiders are buying or selling NexgenRx stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NXG Insider Buying and Selling by Quarter Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW NexgenRx Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/14/2024Paul CrossettInsiderBuy20,000C$0.25C$5,000.005/24/2024Ronald Campbell LoucksDirectorBuy120,000C$0.28C$33,600.00 (Data available from 1/1/2013 forward) NXG Insider Trading Activity - Frequently Asked Questions Who is on NexgenRx's Insider Roster? The list of insiders at NexgenRx includes Kelly Tyler Ehler, Paul Crossett, and Ronald Campbell Loucks. Learn more on insiders at NXG. What percentage of NexgenRx stock is owned by insiders? 36.79% of NexgenRx stock is owned by insiders. Learn more on NXG's insider holdings. Which NexgenRx insiders have been buying company stock? The following insiders have purchased NXG shares in the last 24 months: Paul Crossett (C$5,000.00), and Ronald Campbell Loucks (C$33,600.00). How much insider buying is happening at NexgenRx? Insiders have purchased a total of 140,000 NXG shares in the last 24 months for a total of C$38,600.00 bought. NexgenRx Key ExecutivesMr. Ronald C. Loucks B.B.A. (Age 74)Founder, CEO, President & Director Compensation: $313.34kMr. Kelly Elher C.A.CPA, CA, CPA, Chief Financial OfficerMr. Andrew MunroeSenior Vice President of Pharma & Payor PartnersMr. Jason RobinsonSenior Vice President of AdministrationMs. Doreen HarveyLead Human ResourcesMr. Paul Anthony Bolger LL.B.M.B.A., Company SecretaryMr. Avik DebroyFinancial Controller More Insider Trading Tools from MarketBeat Related Companies Theratechnologies Insider Ownership Medexus Pharmaceuticals Insider Ownership Theralase Technologies Insider Ownership SugarBud Craft Growers Insider Ownership Microbix Biosystems Insider Ownership Reliq Health Technologies Insider Ownership KDA Group Insider Ownership Aurora Spine Insider Ownership DIAGNOS Insider Ownership Nova Leap Health Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (CVE:NXG) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexgenRx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexgenRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
